問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李建霖

Recruiting

List

15Cases

2020-04-01 - 2032-06-30

Others

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2023-10-20 - 2028-09-22

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2023-11-01 - 2031-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

2026-04-01 - 2037-12-31

Phase III

Not yet recruiting
A Phase 3, Open-label, Randomized Study to Compare the Efficacy and Safety of Nemtabrutinib (MK-1026) Plus Venetoclax Versus Venetoclax Plus Rituximab in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Following at Least 1 Prior Therapy (BELLWAVE-010)

  • Condition/Disease

    Leukemia, Lymphocytic, Chronic, B-Cell

  • Test Drug

    錠劑

Participate Sites
4Sites

Recruiting4Sites

2026-05-01 - 2033-12-31

Phase III

Active
A Phase 3 Randomized Study Comparing JNJ-79635322 Versus Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma After 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide

  • Condition/Disease

    Multiple Myeloma

  • Test Drug

    皮下注射劑 皮下注射劑

Participate Sites
6Sites

Recruiting6Sites

2024-10-01 - 2028-03-01

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2024-12-30 - 2031-06-26

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2026-02-01 - 2034-11-14

Phase III

Not yet recruiting
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Not yet recruiting1Sites

Recruiting7Sites

2026-05-01 - 2030-01-31

Phase II/III

Not yet recruiting
An Open-Label, Single-arm, Multicenter Phase 2/3 Clinical Trial Evaluating Avatrombopag in Adult Patients with Aplastic Anemia (AA) Refractory to or Ineligible for Immunosuppressive Therapy or with Relapsed AA after Immunosuppressive Therapy

  • Condition/Disease

    Aplastic Anemia

  • Test Drug

    Avatrombopag

Participate Sites
4Sites

Recruiting4Sites

2025-02-28 - 2029-08-15

Phase III

Active
A phase 3, randomized, double-blind, placebo-controlled trial of Bleximenib, Venetoclax, and Azacitidine in newly diagnosed acute myeloid leukemia patients with KMT2A gene recombination or NPM1 gene mutation who were ineligible for high-intensity chemotherapy.

  • Condition/Disease

    Acute myeloid leukemia

  • Test Drug

    Azacitidine Bleximenib Venetoclax

Participate Sites
4Sites

Recruiting4Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB